Cargando…
Pharmacological evidence of bradykinin regeneration from extended sequences that behave as peptidase–activated B(2) receptor agonists
While bradykinin (BK) is known to be degraded by angiotensin converting enzyme (ACE), we have recently discovered that Met-Lys-BK-Ser-Ser is paradoxically activated by ACE. We designed and evaluated additional “prodrug” peptides extended around the BK sequence as potential ligands that could be loca...
Autores principales: | Charest-Morin, Xavier, Roy, Caroline, Fortin, Émile-Jacques, Bouthillier, Johanne, Marceau, François |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3945637/ https://www.ncbi.nlm.nih.gov/pubmed/24639651 http://dx.doi.org/10.3389/fphar.2014.00032 |
Ejemplares similares
-
In Vivo Effects of Bradykinin B(2) Receptor Agonists with Varying Susceptibility to Peptidases
por: Jean, Mélissa, et al.
Publicado: (2016) -
D-Arg(0)-Bradykinin-Arg-Arg, a Latent Vasoactive Bradykinin B(2) Receptor Agonist Metabolically Activated by Carboxypeptidases
por: Bachelard, Hélène, et al.
Publicado: (2018) -
Pharmacological effects of recombinant human tissue kallikrein on bradykinin B(2) receptors
por: Charest-Morin, Xavier, et al.
Publicado: (2015) -
Species-specific pharmacology of maximakinin, an amphibian homologue of bradykinin: putative prodrug activity at the human B(2) receptor and peptidase resistance in rats
por: Charest-Morin, Xavier, et al.
Publicado: (2017) -
In Vitro Pharmacological Profile of a New Small Molecule Bradykinin B(2) Receptor Antagonist
por: Lesage, Anne, et al.
Publicado: (2020)